Under Pressure: Sanofi's Strategy Will Be Tested By Generic Lovenox Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Ahead of the big pharma's earnings call July 29, Sanofi-Aventis is under renewed pressure with Momenta and partner Sandoz promising a swift launch of their newly approved generic version of Lovenox.
You may also be interested in...
Sanofi Stays Mum On Genzyme But Near-Term M&A Appears Likely
Sanofi-Aventis is dangling over a dangerous patent cliff, facing generic competition to Lovenox, Plavix and other top-selling drugs, and the company's solution to scramble back to safer ground could be a significant acquisition
Sanofi Stays Mum On Genzyme But Near-Term M&A Appears Likely
Sanofi-Aventis is dangling over a dangerous patent cliff, facing generic competition to Lovenox, Plavix and other top-selling drugs, and the company's solution to scramble back to safer ground could be a significant acquisition
Sanofi Stays Mum On Genzyme But Near-Term M&A Appears Likely
Sanofi-Aventis is interested in acquiring a company with market cap up to $20 billion, CEO Viehbacher says, leaving open the possibility of acquiring Genzyme.